ER+ breast cancers are largely dependent on estrogen signaling for proliferation and survival [54], with ER inhibition leading to reduced tumor cell viability and cell cycle arrest in the G1 phase [55, 56]. This evidence concerns the gene ESR1 and breast cancer.